Zomedica (ZOM) Stock Price and News: Risk off sees ZOM down 15% early on Tuesday.

  • NYSEAMERICAN:ZOM drops by 15% to $1.775 in Tuesday's first hour.
  • Risk-off appears to be hurting all hyped stocks as retail interest suffers.
  • Zomedica results are due on Wednesday, February 24.

Update: Shares in ZOM suffer a sharp sell-off in the first hour of Tuesday trading. Markets overall are suffering and so those stocks with higher delta (move more than the underlying index) are suffering the most as profit-taking and risk-reducing strategies dominate. Investors will await ZOM results which are due out Wednesday for fuhter information on ZOM's Truforma development.

NYSEAMERICAN:ZOM has been a popular stock to trade for social media investors who are active on forums like Fintwit and Reddit. On Monday, it was clear that some of that momentum has been lost as shares of Zomedica fell by 7.89%, as the volatile performance of global markets carried over from last week. Zomedica’s stock is still up over 500% since the beginning of 2021, which shows that short-term traders have benefited from its recent gains. Long-term investors are hoping to hit a homerun with Zomedica, with an upcoming catalyst that may be a make or break period for the future success of the company.

That catalyst is of course the impending release of its veterinary software platform called Truforma. With Truforma, Zomedica is hoping to revolutionize in-office care for cats and dogs who need to be tested and treated for diseases of the thyroid and adrenal glands. Pet ownership skyrocketed during the COVID-19 pandemic, and there is an anticipated rise in the need for pet healthcare, with an estimated CAGR of 10% per year. Coupled with the fact that Truforma is a potentially revolutionary point-of-care diagnostic tool, and it is easy to see why long-term investors are bullish on the stock.

ZOM stock forecast

ZOM stock price chart

Zomedica will have to prove that its growth was not just due to the recent Reddit movement against Wall Street, as daily trading volume has plummeted over the past few weeks. Unlike other companies like AMC (NYSE:AMC) which already has an established ceiling, the upcoming release of Truforma could prove that Zomedica is for real. 

Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.

Feed news

Latest Forex News

Latest Forex News

Editors’ Picks

GBP/USD holds above 1.4050 after upbeat UK job figures

GBP/USD is trading above 1.4050, near the fresh 35-month highs as US yields retreat from the highs and push the dollar lower. UK wages rose by 4.7% in December and January's jobless claims fell by 20,000, both better than expected. 


DOGE in trouble as multiple technical indicators scream sell

Dogecoin price hints at a 75% upswing as the bull flag pattern develops. A decisive close above $0.058 would indicate a start of a bullish breakout. Mounting selling pressure could invalidate crucial support at $0.047 and push it down by 20% to $0.037.

Read more

EUR/USD under pressure ahead of Powell's testimony

EUR/USD trades at fresh daily lows sub-1.2150, with investors turning cautious ahead of the Fed Chairman Powell's appearance before Congress. US Treasury yields under mild pressure, equities struggling to turn green.


XAU/USD remains confined in a range above 200-hour SMA

A combination of diverging forces failed to provide any meaningful impetus to gold on Tuesday. Acceptance above 200-hour SMA/23.6% Fibo. confluence supports prospects for additional gains. Mixed oscillators warrant some caution before positioning for any further appreciating move.

Gold news

US Dollar Index: Formidable support is located at 90.00

DXY tests and rebound from the key 90.00 neighbourhood. Further south of this level comes in the 2021 lows at 89.20.

US Dollar Index News